Menu
Log in
Forgot password
Log in


Asian American Academy of Science and Engineering

David D. Ho, M.D.

Professor of Microbiology & Immunology, Clyde '56 and Helen Wu Professor of Medicine and Director, Aaron Diamond AIDS Research Center
Member, National Academy of Medicine
Member, American Academy of Arts & Sciences
Fellow, American Association for the Advancement of Science
M.D., Harvard Medical School

Selected Publications

  1. Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Gordon A, Wang HH, Liu L, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 2023; 624, 639-644.
  2. Liu L, Casner RG, Guo Y, Wang Q, Iketani S, Chan JF, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity 2023; 56(10):2442-2455.e8. PMID: 37776849
  3. Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, Bian Q, Wang H, Sun H, Hong SJ, Culbertson B, Mohri H, Luck MI, Zhu Y, Liu X, Lu Y, Yang X, Yang K, Sabo Y, Chavez A, Goff SP, Rao Z, Ho DD, Yang H.  Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.  Nature 2023; 622(7982):376-382. PMID: 37696289
  4. Tsuji M, Nair MS, Masuda K, Castagna C, Chong Z, Darling TL, Seehra K, Hwang Y, Ribeiro AL, Ferreira GM, Corredor L, Alves Coelho-dos-Reis JG, Tsuji Y, Mori M, Boon ACM, Diamond MS, Huang Y, Ho DD. An immunostimulatory Glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo. Nature Comm. 2023; 14(1):3959.
  5. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD.  Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.  Cell 2023; 186(2):279-286. PMID: 36580913.
  6. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD.  Antibody responses to Omicron BA.4-BA.5 bivalent booster.  N. Engl. J. Med. 2023; 388(6):567-569. PMID: 36630643.
  7. Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 2023; 613(7944):558-564. PMID: 36351451.
  8. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen A, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers KA, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. Nature 2022; 608(7923):603-608. PMID: 35790190.
  9. Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, Mohri H, Ho DD. Rebound of SARS-CoV-2 infection after Nirmatrelvir-Ritonavir treatment. N. Engl. J. Med. 2022; 387(11):1045-1047. PMID: 36069968.
  10. Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.  Nature 2022; 604(7906):553-556. PMID: 35240676.
  11. Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY, Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-681. PMID: 35016198.
  12. Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L, Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci. Transl. Med., 2022; 14(646):eabn6859. PMID: 35438546.
  13. Annavajhala MK, Mohri H, Wang P, Nair M, Zucker JE, Sheng Z, Gomez-Simmonds A, Kelley AL, Tagliavia M, Huang Y, Bedford T, Ho DD, Uhlemann AC. Emergence and expansion of SARS-CoV-2 B.1.526 after indentification in New York. Nature 2021; 597(7878):703-708.
  14. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yi MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021; 593(7837):130-135.
  15. Liu L, Wang P, Nair MS, Yu J, Rapp MA, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Potent neutralizing antibodies against multiple epitopes on the SARS-CoV-2 spike. Nature 2020; 584(7821):450-456. PMID: 32698192.
  16. Huang Y, Yu J, Lanzi A, Andrews CD, Yao X, Sun M, Seaman MS, Padte NN, Ho DD.  Engineered bispecific antibodies with exquisite HIV-1 neutralizing activity.  Cell 2016; 165:1621-1631.
  17. Andrews CD, Yueh YL, Spreen WR, Bernard LS, Boente-Carrera M, Rodriguez K, Gettie A, Russell-Lodrigue K, Blanchard J, Ford S, Mohri H, Cheng-Mayer C, Hong Z, Ho DD, Markowitz M.  Long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenges.  Sci. Transl. Med. 2015; 7(270):270ra4. 
  18. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrique K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD.  Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.  Science 2014; 343:1151-1154.
  19. Song R, Oren DA, Franco D, Seaman MS, Ho DD.  Strategic addition of an N-linked glycan to a monoclonal antibody improves its anti-HIV-1-neutralizing activity.  Nature Biotech. 2013; 31:1047-1053.
  20. Ho DD, Bieniasz PD.  HIV-1 at 25.  Cell 2008; 133:561-565.
  21. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, La Mar M, Wrin T, Parkin N, Poles M, Petropoulos C, Mullen M, Boden D, Ho DD.  Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.  Lancet 2005; 365:1031-1038.
  22. Mohri H, Perelson AS, Tung K, Ribeiro R, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, Hellerstein MK, Ho DD.  Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy.  J. Exp. Med. 2001; 194:1277-1287.
  23. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy.  Nature Med. 2000; 6:76-81.
  24. Zhang L, Lewin S, Markowitz M, Lin H-H, Skulsky E, Karanicolas R, He Y, Jin X, Tuttleton S, Vesanen M, Spiegel H, Kost R, J. van Lunzen, H-J. Stellbrink, Wolinsky S, Borkowsky W, Palumbo P, Kostrikis LG, Ho DD.  Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.  J. Exp. Med. 1999; 190:725-732.
  25. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler, Markowitz M, Moore JP, Perelson AS, Ho DD.  Rapid production and clearance of HIV-1 and hepatitis C virus particles in infected individuals as defined by large volume plasma apheresis.  Lancet 1999; 354:1782-1785.
  26. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Kostrikis L, Blanchard J, Irwin CE, Safrit JT, Zhang L, Ho DD.  Dramatic rise in plasma viremia after CD8+ T-cell depletion in simian immunodeficiency virus-infected macaques.  J. Exp. Med. 1999; 189:991-998.
  27. Zhang L, Ramratnam B, Tenner-Racz, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.  Quantifying residual HIV-1 replication in patients receiving effective combination antiretroviral therapy.  N. Engl. J. Med. 1999; 340:1605-1613.
  28. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.  Science 1998; 279:1223-1227.
  29. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD.  An African HIV-1 sequence from 1959 and implications for the origin of the epidemic.  Nature 1998; 391:594-597.
  30. Ho DD, Huang Y.  The HIV-1 vaccine race.  Cell 2002; 110:135-138.
  31. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD.  Decay characteristics of HIV-1-infected compartments during combination therapy.  Nature 1997; 387:188-191.
  32. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau N, Phair J, Ho DD, Koup RA.  The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.  Nature Med. 1996; 2:1240-1243.
  33. Ho DD.  Viral counts count in HIV infection.  Science 1996; 272:1124-1125.
  34. Perelson AS, Neumann AU, Markowitz M, Leonard J, Ho DD.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.  Science 1996; 271:1582-1586.
  35. Markowitz M, Saag M, Powderly W, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, Ho DD.  A preliminary study of ritonavir, an inhibitor of hiv-1 protease, to treat HIV-1 infection.  N. Engl. J. Med. 1995; 333:1534-1539.
  36. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M.  Rapid turnover of plasma virion and CD4 lymphocytes in HIV-1 infection.  Nature 1995; 373:123-126.
  37. Ho DD.  Time to hit HIV, early and hard.  N. Engl. J. Med. 1995; 333:450-451.
  38. Cao Y, Qing L, Zhang GL, Safrit J, Ho DD. Virological and immunological characterization of long-term survivors of HIV-1 infections.  N. Engl. J. Med. 1995; 332:201-208.
  39. Koup RA, Ho DD.  Shutting down HIV.  Nature 1994; 370:416.
  40. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup R, Ho DD.  Genotypic and phenotypic characterization of HIV-1 in patients with primary infection.  Science 1993; 261:1179-1181.
  41. Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley RT, Daar ES.  Idiopathic CD4+ T-lymphocytopenia (ICL): immunodeficiency without evidence of human immunodeficiency virus infection.  N. Engl. J. Med. 1993; 328:380-385.
  42. Daar ES, Moudgil T, Meyer RD, Ho DD.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.  N. Engl. J. Med. 1991; 324:961-964.
  43. Ho DD, Moudgil T, Alam M.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.  N. Engl. J. Med. 1989; 321:1621-1625.
  44. Melish ME, Marchette NJ, Kaplan JC, Kihara S, Ching D, Ho DD.  Absence of significant RNA-dependent DNA polymerase activity in lymphocytes from patients with Kawasaki syndrome.  Nature 1989; 337:288-290.
  45. Ho DD, Rota TR, Hirsch MS.  Infection of monocyte-macrophages by human T-lymphotropic virus type III.  J. Clin. Investig. 1986; 77:1712-1715.
  46. Ho DD, Sarngadharan MG, Resnick L, diMarzo-Veronese F, Rota TR, Hirsch MS.  Primary human T-lymphotropic virus type III infection.  Ann. Intern. Med. 1985; 103:880-883.
  47. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, Resnick L, Felsenstein D, Andrews CA, Hirsch MS.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.  N. Engl. J. Med. 1985; 313:1493-1497.
  48. Ho DD, Schooley RT, Rota TR, Kaplan JC, Salahuddin SZ, Gonda MA, Hirsch MS.  HTLV-III in semen and blood of a healthy homosexual man.  Science 1984; 226:451-453.
Powered by Wild Apricot Membership Software